Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
Abstract Ankylosing spondylitis is a chronic, progressive disease, and its treatment is relevant to the gut microbiota. Anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease. However, little is known about the effect of...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | MicrobiologyOpen |
Subjects: | |
Online Access: | https://doi.org/10.1002/mbo3.927 |
id |
doaj-1c8540f8f2ed4669a6e625c27a29b297 |
---|---|
record_format |
Article |
spelling |
doaj-1c8540f8f2ed4669a6e625c27a29b2972020-11-25T00:16:07ZengWileyMicrobiologyOpen2045-88272019-12-01812n/an/a10.1002/mbo3.927Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in miceBin Liu0Lianjun Yang1Zhifei Cui2Junchi Zheng3Jincheng Huang4Qinghao Zhao5Zhihai Su6Min Wang7Weicong Zhang8Jinshi Liu9Tingxuan Wang10Qingchu Li11Hai Lu12Department of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaDepartment of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaDepartment of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Orthopedics, Henan Provincial People's Hospital Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaDepartment of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Orthopedic Surgery, Academy of Orthopedics of Guangdong Province, Orthopaedic Hospital of Guangdong Province, The Third Affiliated Hospital Southern Medical University Guangzhou ChinaDepartment of Spine surgery The Fifth Affiliated Hospital, Sun Yat‐sen University Zhuhai Guangdong ChinaAbstract Ankylosing spondylitis is a chronic, progressive disease, and its treatment is relevant to the gut microbiota. Anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease. However, little is known about the effect of TNF‐α blocker treatment on the gut microbiota in ankylosing spondylitis. Herein, the effect of a TNF‐α blocker on the gut microbiota in proteoglycan‐induced arthritis was investigated. Proteoglycan‐induced mice were treated with an rhTNFR:Fc solution of etanercept (5 µg/g) for 4 weeks. rhTNFR:Fc treatment attenuated the arthritis incidence and severity of arthritis in the proteoglycan‐induced mice and decreased inflammation in the ankle joints and ameliorated ileal tissue destruction. Moreover, high gut permeability occurred, and zonula occludens‐1 and occludin protein levels were reduced in proteoglycan‐induced mice. These levels were significantly restored by the administration of rhTNFR:Fc. The serum TNF‐α and IL‐17 levels were also decreased. In addition, flora analysis via 16S rDNA high‐throughput sequencing revealed that rhTNFR:Fc treatment restored the gut microbiota composition to a composition similar to that in control mice. In conclusion, anti‐TNF‐α therapy attenuated proteoglycan‐induced arthritis progression and modulated the gut microbiota and intestinal barrier function. These results provide new insights for anti‐TNF‐α therapy strategies via regulating the gut microbiota in ankylosing spondylitis.https://doi.org/10.1002/mbo3.92716S rDNA high‐throughput sequencingankylosing spondylitisanti‐TNF‐alpha therapygut microbiotaproteoglycan‐induced mice |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bin Liu Lianjun Yang Zhifei Cui Junchi Zheng Jincheng Huang Qinghao Zhao Zhihai Su Min Wang Weicong Zhang Jinshi Liu Tingxuan Wang Qingchu Li Hai Lu |
spellingShingle |
Bin Liu Lianjun Yang Zhifei Cui Junchi Zheng Jincheng Huang Qinghao Zhao Zhihai Su Min Wang Weicong Zhang Jinshi Liu Tingxuan Wang Qingchu Li Hai Lu Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice MicrobiologyOpen 16S rDNA high‐throughput sequencing ankylosing spondylitis anti‐TNF‐alpha therapy gut microbiota proteoglycan‐induced mice |
author_facet |
Bin Liu Lianjun Yang Zhifei Cui Junchi Zheng Jincheng Huang Qinghao Zhao Zhihai Su Min Wang Weicong Zhang Jinshi Liu Tingxuan Wang Qingchu Li Hai Lu |
author_sort |
Bin Liu |
title |
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
title_short |
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
title_full |
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
title_fullStr |
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
title_full_unstemmed |
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
title_sort |
anti‐tnf‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice |
publisher |
Wiley |
series |
MicrobiologyOpen |
issn |
2045-8827 |
publishDate |
2019-12-01 |
description |
Abstract Ankylosing spondylitis is a chronic, progressive disease, and its treatment is relevant to the gut microbiota. Anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease. However, little is known about the effect of TNF‐α blocker treatment on the gut microbiota in ankylosing spondylitis. Herein, the effect of a TNF‐α blocker on the gut microbiota in proteoglycan‐induced arthritis was investigated. Proteoglycan‐induced mice were treated with an rhTNFR:Fc solution of etanercept (5 µg/g) for 4 weeks. rhTNFR:Fc treatment attenuated the arthritis incidence and severity of arthritis in the proteoglycan‐induced mice and decreased inflammation in the ankle joints and ameliorated ileal tissue destruction. Moreover, high gut permeability occurred, and zonula occludens‐1 and occludin protein levels were reduced in proteoglycan‐induced mice. These levels were significantly restored by the administration of rhTNFR:Fc. The serum TNF‐α and IL‐17 levels were also decreased. In addition, flora analysis via 16S rDNA high‐throughput sequencing revealed that rhTNFR:Fc treatment restored the gut microbiota composition to a composition similar to that in control mice. In conclusion, anti‐TNF‐α therapy attenuated proteoglycan‐induced arthritis progression and modulated the gut microbiota and intestinal barrier function. These results provide new insights for anti‐TNF‐α therapy strategies via regulating the gut microbiota in ankylosing spondylitis. |
topic |
16S rDNA high‐throughput sequencing ankylosing spondylitis anti‐TNF‐alpha therapy gut microbiota proteoglycan‐induced mice |
url |
https://doi.org/10.1002/mbo3.927 |
work_keys_str_mv |
AT binliu antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT lianjunyang antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT zhifeicui antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT junchizheng antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT jinchenghuang antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT qinghaozhao antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT zhihaisu antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT minwang antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT weicongzhang antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT jinshiliu antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT tingxuanwang antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT qingchuli antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice AT hailu antitnfatherapyaltersthegutmicrobiotainproteoglycaninducedankylosingspondylitisinmice |
_version_ |
1725384463784869888 |